Backed by leading U.S.-based life sciences venture capital firm Domain Associates, Domain Russia Investments (DRI) develops and invests in projects that drive innovation in the health sciences sector in Russia and its neighboring countries. DRI plays a crucial role in Domain’s strategic collaboration with RUSNANO Corporation, the largest Russian state-owned venture capital fund.Read more
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
Technology Center’s R&D labs were put into operation in the end of 2016 and now they are already working under five projects within the own NovaMedica research program. Further four projects are to start in the course of the year. These drugs have innovative delivery system of active ingredients, which changes bioavailability of drugs and allows to combine incompatible previously substances in one dosage form. As a result, drugs under development will obtain new administration possibilities and they fundamentally surpass a number of analogue drugs in efficacy and safety.
Pfizer and NovaMedica have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.
Domain Associates, a leading life sciences venture capital firm, announces a fifth portfolio company, ReVision Optics, has received funding under its investment agreement with Russian state investment corporation Rusnano. ReVision Optics is a Southern California-based firm developing Raindrop™, an inlay for presbyopic vision correction in Phase III trials. ReVision Optics has raised $55 million in a financing in which Domain, Rusnano subsidiary RusnanoMedInvest and other investors participated.